AXSM Axsome Therapeutics, Inc.

5.55
+0  (0%)
Previous Close 5.55
Open 5.50
Price To book 3.77
Market Cap 106.30M
Shares 19,153,000
Volume 58,811
Short Ratio 11.73
Av. Daily Volume 29,924

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 to be initiated 1H 2017.
AXS-05
Agitation in patients with Alzheimer’s disease (AD)
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 1Q or 2Q 2017.
AXS-02
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Continues to enroll as of November 2016.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 commenced March 2016. Continues to enroll as of November 2016.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 planned. IND to be filed by end of 2016.
AXS-02
Chronic Low Back Pain Associated with Modic Changes

Latest News

  1. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  2. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
  3. Axsome Therapeutics to Present at Biotech Showcase 2017
  4. Axsome Therapeutics Receives FDA Clearance of IND for Phase 2/3 Trial of AXS-05 in Alzheimer’s Disease Agitation
  5. AXSOME THERAPEUTICS, INC. Financials
  6. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  7. Axsome Therapeutics Reports Third Quarter 2016 Financial Results
  8. AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  9. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financ
  10. Axsome Therapeutics Enters into $20 Million Term Loan Agreement with Silicon Valley Bank
  11. Anavex Life Sciences Joins The Club Of Stocks Moving Higher On News Of Alzheimer's Research
  12. Axsome Therapeutics: Teaching Old Drugs New Tricks
  13. 5 Stocks Under $10 Poised for Big Breakouts
  14. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stat
  15. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
  16. AXSOME THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report
  17. AXSOME THERAPEUTICS, INC. Files SEC form 10-Q/A, Quarterly Report
  18. AXSOME THERAPEUTICS, INC. Files SEC form 10-K/A, Annual Report
  19. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
  20. AXSOME THERAPEUTICS, INC. Files SEC form 8-K, Non-Reliance on Previous Financials, Audits or Interim Review

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17527259
  2. 8-K - Current report 17526013
  3. 8-K - Current report 17506866
  4. EFFECT - Notice of Effectiveness 162057728
  5. S-3 - Registration statement under Securities Act of 1933 162028409
  6. 8-K - Current report 161995388
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161994696
  8. 8-K - Current report 161988477
  9. 8-K - Current report 161869306
  10. 8-K - Current report 161819574